急性冠脉综合征后动脉粥样硬化血栓形成的长期预防药物治疗
该综述指出急性冠脉综合征(ACS)后动脉粥样硬化血栓事件风险可持续多年,病理生理学进展从单一「易损斑块」转向「易损患者」整体观,凸显药物治疗在二级预防中的核心地位。尽管遵循指南导向药物治疗,部分患者仍因残余风险发生复发性动脉粥样硬化血栓形成,近期临床试验强调血小板、凝血、胆固醇和全身炎症的关键作用,并支持个体化靶向治疗策略。
要点
- ACS后动脉粥样硬化血栓风险持续多年,需长期二级预防。
- 病理生理学从「易损斑块」转向「易损患者」整体观,强调药物治疗核心地位。
- 指南导向治疗后仍有残余风险,涉及血小板、凝血、胆固醇和炎症,支持个体化靶向治疗。
核心结论
- ACS后动脉粥样硬化血栓形成风险可持续多年,药物治疗是长期二级预防的基石。
- 尽管遵循指南导向药物治疗,部分患者仍因残余风险发生复发性动脉粥样硬化血栓形成。
- 近期临床试验强调血小板、凝血、胆固醇和全身炎症在残余风险中的关键作用,支持个体化靶向治疗。
研究设计与样本
- 本文为JACC state-of-the-art综述,总结ACS后动脉粥样硬化血栓形成二级预防的进展证据。
主要发现
- ACS后对动脉粥样硬化血栓事件的易感性可持续多年。
- 对ACS病理生理学的认识从单一「易损斑块」转向「易损患者」整体观。
- 指南导向药物治疗后,部分ACS后患者仍发生复发性动脉粥样硬化血栓形成。
- 近期临床试验强调血小板、凝血、胆固醇和全身炎症在残余风险中的作用。
- 新兴数据揭示此前未认识的残余风险因素。
临床怎么用
- ACS后应坚持长期二级预防药物治疗,并关注指南导向治疗后的残余风险。
- 残余风险管控需综合考虑血小板、凝血、胆固醇和全身炎症等靶点。
- 基于残余风险因素探索个体化、靶向的二级预防策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Following an acute coronary syndrome (ACS), heightened predisposition to atherothrombotic events may persist for years. Advances in understanding the pathobiology that underlies this elevated risk furnish a mechanistic basis for devising long-term secondary prevention strategies. Recent progress in ACS pathophysiology has challenged the focus on single "vulnerable plaques" and shifted toward a more holistic consideration of the "vulnerable patient," thus highlighting the primacy of medical therapy in secondary prevention. Despite current guideline-directed medical therapy, a consistent proportion of post-ACS patients experience recurrent atherothrombosis due to unaddressed "residual risk": contemporary clinical trials underline the pivotal role of platelets, coagulation, cholesterol, and systemic inflammation and provide a perspective on a personalized, targeted approach. Emerging data sheds new light on heretofore unrecognized residual risk factors. This review aims to summarize evolving evidence relative to secondary prevention of atherothrombosis, with a focus on recent advances that promise to transform the management of the post-ACS patient.
引用
- Gallone G, Baldetti L, Pagnesi M, et al. Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018. PMID: 30522652. doi:10.1016/j.jacc.2018.09.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。